商务合作
动脉网APP
可切换为仅中文
Drug maker
药品制造商
Cipla
西普拉
on Friday said it has launched an integrated lung diagnostics and wellness centre in the national capital.
周五表示,已在首都推出了一个综合的肺部诊断和健康中心。
Located in Lajpat Nagar, it will be India's first-of-its-kind integrated lung diagnostics and wellness centre, the company said.
该公司表示,该中心位于拉杰帕特纳加尔,将成为印度首个综合肺部诊断和健康中心。
It is set to redefine respiratory care by making advanced standardised lung diagnostics both accessible and affordable for doctors and patients across the country, it said.
它表示,此举将通过让全国各地的医生和患者都能够负担得起先进的标准化肺部诊断来重新定义呼吸系统护理。
'Cipla has long been a pioneer in respiratory care, and with the launch of the first
“Cipla一直在呼吸系统护理领域处于先锋地位,随着首个
Breathefree Lung Wellness Center
呼吸自由肺部健康中心
, we are addressing a critical gap in the diagnostic landscape,'
“我们正在解决诊断领域中的一个关键空白。”
Cipla Ltd
印度西普拉有限公司
Global Chief Operating Officer Achin Gupta said.
全球首席运营官阿钦·古普塔表示。
The centre will provide a comprehensive gamut of over 60 tests covering lung physiology, microbiology, immunology, blood chemistry and radiology.
该中心将提供涵盖肺生理学、微生物学、免疫学、血液化学和放射学的60多项综合测试。
Live Events
现场活动
The aim is to enable a more comprehensive evaluation of the lungs for patients suspected of having a respiratory disease or those already diagnosed with a lung condition - ranging from common diseases like Asthma and COPD to more complex ones such as interstitial lung diseases (ILD), it added.
其目的是对疑似患有呼吸道疾病或已确诊肺部疾病的患者进行更全面的肺部评估——涵盖从哮喘和慢性阻塞性肺病(COPD)等常见疾病到间质性肺病(ILD)等更为复杂的疾病。
Respiratory diseases have been on the rise in India, with millions remaining undiagnosed or misdiagnosed due to limited access to advanced pulmonary function testing and comprehensive diagnostic infrastructure in the respiratory domain.
印度的呼吸系统疾病一直在增加,由于在呼吸领域缺乏先进的肺功能测试和全面的诊断基础设施,数百万人仍未得到诊断或被误诊。
Add
添加
as a Reliable and Trusted News Source
作为一个可靠和值得信赖的新闻来源
Add Now!
立即添加!
(You can now subscribe to our
(你现在可以订阅我们的
Economic Times WhatsApp channel
经济时报WhatsApp频道
)
)
(You can now subscribe to our
(您现在可以订阅我们的
Economic Times WhatsApp channel
经济时报WhatsApp频道
)
)